The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities

The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
Executive Summary 12

The macroeconomic environment in the Middle East 12

Healthcare systems in the Middle East 13

Pharmaceutical market analysis of the Middle East 14

Competitive landscape of the Middle Eastern pharmaceutical market 15

Scope and Methodology 18

Scope 18

Methodology 18

Chapter 1 The macroeconomic environment in the Middle East 20

Summary 20

Introduction 21

Population profile 22

Disease burden 24

Macroeconomic comparison of the Middle East 30

Economic landscape of key Middle Eastern countries 32

Egypt 32

Turkey 33

Saudi Arabia 34

Israel 35

Jordan 36

UAE 36

Lebanon 38

Kuwait 38

Healthcare spending 39

Chapter 2 Healthcare systems in the Middle East 42

Summary 42

Introduction 43

Profiles of the healthcare systems across Middle Eastern countries 43

Egypt 43

Healthcare system 43

Intellectual property rights 44

Pricing and reimbursement 45

Key recent events 46

Turkey 47

Healthcare system 47

Intellectual property rights 49

Pricing and reimbursement 50

Key recent events 52

Saudi Arabia 53

Healthcare system 53

Intellectual property rights 54

Pricing and reimbursement 55

Key recent events 57

Israel 58

Healthcare system 58

Intellectual property rights 58

Pricing and reimbursement 59

Key recent events 61

Jordan 62

Healthcare system 62

Intellectual property rights 63

Pricing and reimbursement 63

Key recent events 64

UAE 65

Healthcare system 65

Intellectual property rights 66

Pricing and reimbursement 67

Key recent events 68

Lebanon 68

Healthcare system 68

Intellectual property rights 69

Pricing and reimbursement 70

Key recent events 71

Kuwait 71

Healthcare system 71

Intellectual property rights 72

Pricing and reimbursement 72

Key recent events 73

Chapter 3 Pharmaceutical Market analysis in the Middle East 76

Summary 76

Introduction 77

Pharmaceutical market overview 77

Therapy area analysis 80

Therapy area sales forecast 81

Therapy area analysis by country 82

Egypt 82

Turkey 85

Saudi Arabia 88

Israel 90

Jordan 93

UAE 94

Lebanon 97

Kuwait 100

Leading brands analysis 103

Seretide (GSK) 104

Lipitor (Pfizer) 104

Augmentin (GSK/MUP) 104

Glivec (Novartis) 105

Co-Diovan (Novartis) 105

Spiriva (Boehringer Ingelheim) 106

Plavix (Sanofi-Aventis) 106

Cipralex (Lundbeck) 107

Lansor (Sanovel) 107

Symbicort (AstraZeneca) 108

Leading brands sales forecast 108

Key brand analysis by country 110

Egypt 110

Flumox and Cefotax (Eipico) 110

Amaryl (Sanofi-Aventis) 111

Cataflam (Novartis) 111

Augmentin (MUP) 111

Turkey 112

Foradil Combi (Novartis) 113

Taxotere (Sanofi-Aventis) 113

Herceptin (Roche) 114

Saudi Arabia 114

Augmentin (GSK) 115

Snafi (Spimaco) 116

Viagra (Pfizer) 116

Nexium (AstraZeneca) 116

Israel 116

Norditropin (Novo Nordisk) 117

Seretide (GSK) 118

Tritace (Sanofi-Aventis) 118

Jordan 118

Amoclan (Hikma) 119

Similac Gain and Similac Advance (Abbott Nutrition) 119

Cerelac (Nestle) 120

United Arab Emirates 121

Cialis (Eli Lilly) 121

Plavix (Sanofi-Aventis) 122

Zinnat (GSK) 122

Lebanon 122

Pariet (J&J) 123

Concor (Merck KGaA) 123

Crestor (AstraZeneca) 124

Kuwait 124

Rocephin (Roche) 125

Xenical (Roche) 125

Yasmin (Bayer) 126

Chapter 4 Competitive landscape of the Middle Eastern pharmaceutical

market 128

Summary 128

Introduction 129

Leading players 129

Analysis of key players in the Middle East 133

Novartis 133

Overview 133

Sales focus by leading drug class 133

Marketed product portfolio 135

Novartis' pipeline focus 138

Strategic growth analysis 139

GSK 142

Overview 142

Sales focus by leading drug class 142

Marketed product portfolio 144

GSK's pipeline focus 146

Strategic growth analysis 147

Sanofi-Aventis 150

Overview 150

Sales focus by leading drug class 150

Marketed product portfolio 152

Sanofi-Aventis pipeline focus 154

Strategic growth analysis 155

Pfizer 157

Overview 157

Sales focus by leading drug class 157

Marketed product portfolio 159

Pfizer's pipeline focus 161

Strategic growth analysis 162

Ibrahim 165

Overview 165

Sales focus by leading drug class 166

Marketed product portfolio 167

Ibrahim's pipeline focus 169

Strategic growth analysis 169

Leading players analysis by country 171

Egypt 171

Turkey 172

Saudi Arabia 174

Israel 176

Jordan 178

UAE 180

Lebanon 182

Kuwait 183

Chapter 5 Appendix 186

Anatomical therapeutic classification (ATC) 186

A: Alimentary tract and metabolism 186

B: Blood and blood-forming organs 186

C: Cardiovascular system 186

D: Dermatologicals 187

G: Genitourinary system and sex hormones 187

H: Systemic hormonal preparations 187

J: General anti-infectives systemic 187

K: Hospital solutions 187

L: Antineoplastic and immunomodulating agents 187

M: Musculoskeletal system 188

N: Nervous system 188

P: Parasitology 188

R: Respiratory system 188

S: Sensory organs 188

T: Diagnostic agents 188

V: Various 189

Forecast factors 189

Glossary 190

Index 191

List of Figures

Figure 1.1: GDP composition by sector in key Middle East countries, 2008 32

Figure 1.2: Comparison of healthcare expenditure across major Middle Eastern countries 39

Figure 3.3: Middle East pharmaceutical market share by countries, 2008 79

Figure 3.4: Top 10 drug classes in the Egyptian pharmaceutical market, 2008 ($m) 85

Figure 3.5: Top 10 drug classes in the Turkish pharmaceutical market, 2008 ($m) 87

Figure 3.6: Top 10 drug classes in the Saudi Arabian pharmaceutical market, 2008 ($m) 90

Figure 3.7: Top 10 drug classes in the Israel pharmaceutical market, 2008 ($m) 92

Figure 3.8: Top 10 drug classes in the Jordanian pharmaceutical market, 2008 ($m) 94

Figure 3.9: Top 10 drug classes in the UAE pharmaceutical market, 2008 ($m) 97

Figure 3.10: Top 10 drug classes in the Lebanese pharmaceutical market, 2008 ($m) 100

Figure 3.11: Top 10 drug classes in the Kuwaiti pharmaceutical market, 2008 ($m) 102

Figure 4.12: Market share of top 10 and other players in the Middle East pharmaceutical market, 2008 132

Figure 4.13: Novartis' Middle East pharmaceutical market sales by therapy area, 2008 134

Figure 4.14: GSK's Middle East pharmaceutical market sales by therapy area, 2008 143

Figure 4.15: Sanofi-Aventis' Middle East pharmaceutical market sales by therapy area, 2008 151

Figure 4.16: Pfizer's Middle East pharmaceutical market sales by therapy area, 2008 158

Figure 4.17: Ibrahim's Middle East pharmaceutical market sales by therapy area, 2008 166

List of Tables

Table 1.1: Demographic profile of key Middle East countries 23

Table 1.2: Forecast epidemiology of common risk factors in Egypt, 2008–14 25

Table 1.3: Forecast epidemiology of common risk factors in Turkey, 2008–14 25

Table 1.4: Forecast epidemiology of common risk factors in Saudi Arabia, 2008–14 26

Table 1.5: Forecast epidemiology of common risk factors in Israel, 2008–14 27

Table 1.6: Forecast epidemiology of common risk factors in Jordan, 2008–14 27

Table 1.7: Forecast epidemiology of common risk factors in UAE, 2008–14 28

Table 1.8: Forecast epidemiology of common risk factors in Lebanon, 2008–14 29

Table 1.9: Forecast epidemiology of common risk factors in Kuwait, 2008–14 30

Table 1.10: Key economic metrics of Middle East countries, 2008 31

Table 3.11: Pharmaceutical sales in major Middle East countries, 2008 78

Table 3.12: Middle East pharmaceutical sales by therapy area, 2008 81

Table 3.13: Middle East pharmaceutical market sales forecast by ATC code, 2008–14 82

Table 3.14: Egypt's pharmaceutical market by therapy area sales, 2008 83

Table 3.15: Turkey's pharmaceutical market by therapy area sales, 2008 86

Table 3.16: Saudi Arabia's pharmaceutical market break-down by therapy area sales, 2008 89

Table 3.17: Israel's pharmaceutical market by therapy area sales, 2008 91

Table 3.18: Jordan's pharmaceutical market breakdown by therapy area sales, 2008 93

Table 3.19: UAE's pharmaceutical market by therapy area sales, 2008 96

Table 3.20: Lebanon's pharmaceutical market by therapy area sales, 2008 98

Table 3.21: Kuwait's pharmaceutical market by therapy area sales, 2008 101

Table 3.22: Leading brands in the Middle East pharmaceutical market, 2008 103

Table 3.23: Leading brand sales forecast, 2008–14 109

Table 3.24: Leading brands in the Egyptian pharmaceutical market, 2008 110

Table 3.25: Leading brands in the Turkish pharmaceutical market, 2008 112

Table 3.26: Leading brands in the Saudi Arabian pharmaceutical market, 2008 115

Table 3.27: Leading brands in the Israeli pharmaceutical market, 2008 117

Table 3.28: Leading brands in the Jordanian pharmaceutical market, 2008 119

Table 3.29: Leading brands in the UAE pharmaceutical market, 2008 121

Table 3.30: Leading brands in the Lebanese pharmaceutical market, 2008 123

Table 3.31: Leading brands in the Kuwaiti pharmaceutical market, 2008 125

Table 4.32: Leading companies in the Middle East pharmaceutical market, 2008 130

Table 4.33: Novartis' leading brands in the Middle East market, 2008 136

Table 4.34: GSK's leading brands in the Middle East market, 2008 145

Table 4.35: Sanofi-Aventis' leading brands in the Middle East market, 2008 152

Table 4.36: Pfizer's leading brands in the Middle East market, 2008 159

Table 4.37: Ibrahim's leading brands in the Middle East market, 2008 168

Table 4.38: Leading companies in the Egyptian pharmaceutical market, 2008 171

Table 4.39: Leading companies in the Turkish pharmaceutical market, 2008 173

Table 4.40: Leading companies in the Saudi Arabian pharmaceutical market, 2008 175

Table 4.41: Leading companies in the Israeli pharmaceutical market, 2008 177

Table 4.42: Leading companies in the Jordanian pharmaceutical market, 2008 179

Table 4.43: Leading companies in the UAE pharmaceutical market, 2008 181

Table 4.44: Leading companies in the Lebanese pharmaceutical market, 2008 182

Table 4.45: Leading companies in the Kuwaiti pharmaceutical market, 2008 184